Literature DB >> 28357536

Pediatric high-grade glioma: current molecular landscape and therapeutic approaches.

Steve Braunstein1, David Raleigh2, Ranjit Bindra3, Sabine Mueller4, Daphne Haas-Kogan5.   

Abstract

High-grade pediatric central nervous system glial tumors are comprised primarily of anaplastic astrocytomas (AA, WHO grade III) and glioblastomas (GBM, WHO grade IV). High-grade gliomas are most commonly diagnosed in the primary setting in children, but as in adults, they can also arise as a result of transformation of a low-grade malignancy, though with limited frequency in the pediatric population. The molecular genetics of high-grade gliomas in the pediatric population are distinct from their adult counterparts. In contrast to the adult population, high-grade gliomas in children are relatively infrequent, representing less than 20% of cases.

Entities:  

Keywords:  Pediatric astrocytoma; Pediatric brain tumor; Pediatric glioblastoma

Mesh:

Year:  2017        PMID: 28357536     DOI: 10.1007/s11060-017-2393-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  79 in total

1.  Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group.

Authors:  A C Grovas; J M Boyett; K Lindsley; M Rosenblum; A J Yates; J L Finlay
Journal:  Med Pediatr Oncol       Date:  1999-08

Review 2.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

3.  Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.

Authors:  Ian F Pollack; Ronald L Hamilton; C David James; Sydney D Finkelstein; Judith Burnham; Allan J Yates; Emiko J Holmes; Tianni Zhou; Jonathan L Finlay
Journal:  J Neurosurg       Date:  2006-11       Impact factor: 5.115

4.  PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.

Authors:  Sabine Mueller; Joanna Phillips; Arzu Onar-Thomas; Eloy Romero; Shichun Zheng; John K Wiencke; Sean M McBride; Cynthia Cowdrey; Michael D Prados; William A Weiss; Mitchel S Berger; Nalin Gupta; Daphne A Haas-Kogan
Journal:  Neuro Oncol       Date:  2012-06-29       Impact factor: 12.300

5.  HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.

Authors:  S Harrow; V Papanastassiou; J Harland; R Mabbs; R Petty; M Fraser; D Hadley; J Patterson; S M Brown; R Rampling
Journal:  Gene Ther       Date:  2004-11       Impact factor: 5.250

Review 6.  A critical review of the clinical effects of therapeutic irradiation damage to the brain: the roots of controversy.

Authors:  Carol L Armstrong; Kunsang Gyato; Abdel W Awadalla; Robert Lustig; Zelig A Tochner
Journal:  Neuropsychol Rev       Date:  2004-03       Impact factor: 7.444

7.  Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945.

Authors:  J H Wisoff; J M Boyett; M S Berger; C Brant; H Li; A J Yates; P McGuire-Cullen; P A Turski; L N Sutton; J C Allen; R J Packer; J L Finlay
Journal:  J Neurosurg       Date:  1998-07       Impact factor: 5.115

8.  Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function.

Authors:  Thomas E Merchant; Chia-Ho Hua; Hemant Shukla; Xiaofei Ying; Simeon Nill; Uwe Oelfke
Journal:  Pediatr Blood Cancer       Date:  2008-07       Impact factor: 3.167

9.  Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.

Authors:  Regina I Jakacki; Kenneth J Cohen; Allen Buxton; Mark D Krailo; Peter C Burger; Marc K Rosenblum; Daniel J Brat; Ronald L Hamilton; Sandrah P Eckel; Tianni Zhou; Robert S Lavey; Ian F Pollack
Journal:  Neuro Oncol       Date:  2016-03-22       Impact factor: 12.300

10.  Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience.

Authors:  Douglas J Hyder; Lillian Sung; Ian F Pollack; Floyd H Gilles; Allen J Yates; Richard L Davis; James M Boyett; Jonathan L Finlay
Journal:  J Neurooncol       Date:  2007-01-25       Impact factor: 4.506

View more
  49 in total

1.  Persistent STAG2 mutation despite multimodal therapy in recurrent pediatric glioblastoma.

Authors:  Christopher S Hong; Juan C Vasquez; Adam J Kundishora; Aladine A Elsamadicy; Jason M Beckta; Amrita Sule; Asher M Marks; Nalin Leelatian; Anita Huttner; Ranjit S Bindra; Michael L DiLuna; Kristopher T Kahle; E Zeynep Erson-Omay
Journal:  NPJ Genom Med       Date:  2020-06-01       Impact factor: 8.617

2.  Successful treatment of a TSC2-mutant glioblastoma with everolimus.

Authors:  Andrew H Zureick; Kathryn A McFadden; Rajen Mody; Carl Koschmann
Journal:  BMJ Case Rep       Date:  2019-05-31

3.  Isolation and characterization of immune cells from the tumor microenvironment of genetically engineered pediatric high-grade glioma models using the sleeping beauty transposon system.

Authors:  Maria Belen Garcia-Fabiani; Andrea Comba; Padma Kadiyala; Santiago Haase; Felipe Javier Núñez; David Altshuler; Pedro Ricardo Lowenstein; Maria Graciela Castro
Journal:  Methods Enzymol       Date:  2019-06-03       Impact factor: 1.600

4.  Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis.

Authors:  Cassie Kline; Erin Felton; I Elaine Allen; Peggy Tahir; Sabine Mueller
Journal:  J Neurooncol       Date:  2017-12-04       Impact factor: 4.130

5.  LncRNA NNT-AS1 promote glioma cell proliferation and metastases through miR-494-3p/PRMT1 axis.

Authors:  Dahai Zheng; Daliang Chen; Famu Lin; Xiang Wang; Lenian Lu; Shi Luo; Jianmin Chen; Xiaobing Xu
Journal:  Cell Cycle       Date:  2020-05-18       Impact factor: 4.534

6.  Radiomics Can Distinguish Pediatric Supratentorial Embryonal Tumors, High-Grade Gliomas, and Ependymomas.

Authors:  M Zhang; L Tam; J Wright; M Mohammadzadeh; M Han; E Chen; M Wagner; J Nemalka; H Lai; A Eghbal; C Y Ho; R M Lober; S H Cheshier; N A Vitanza; G A Grant; L M Prolo; K W Yeom; A Jaju
Journal:  AJNR Am J Neuroradiol       Date:  2022-03-31       Impact factor: 3.825

7.  Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.

Authors:  Débora Cabral de Carvalho Corrêa; Francine Tesser-Gamba; Indhira Dias Oliveira; Nasjla Saba da Silva; Andrea Maria Capellano; Maria Teresa de Seixas Alves; Patrícia Alessandra Dastoli; Sergio Cavalheiro; Silvia Regina Caminada de Toledo
Journal:  J Cancer Res Clin Oncol       Date:  2021-10-09       Impact factor: 4.553

Review 8.  Tumour immune landscape of paediatric high-grade gliomas.

Authors:  James L Ross; Jose Velazquez Vega; Ashley Plant; Tobey J MacDonald; Oren J Becher; Dolores Hambardzumyan
Journal:  Brain       Date:  2021-10-22       Impact factor: 13.501

9.  A first-generation pediatric cancer dependency map.

Authors:  Neekesh V Dharia; Guillaume Kugener; Lillian M Guenther; Clare F Malone; Adam D Durbin; Andrew L Hong; Thomas P Howard; Pratiti Bandopadhayay; Caroline S Wechsler; Iris Fung; Allison C Warren; Joshua M Dempster; John M Krill-Burger; Brenton R Paolella; Phoebe Moh; Nishant Jha; Andrew Tang; Philip Montgomery; Jesse S Boehm; William C Hahn; Charles W M Roberts; James M McFarland; Aviad Tsherniak; Todd R Golub; Francisca Vazquez; Kimberly Stegmaier
Journal:  Nat Genet       Date:  2021-03-22       Impact factor: 38.330

Review 10.  Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.

Authors:  Maria B Garcia-Fabiani; Santiago Haase; Andrea Comba; Stephen Carney; Brandon McClellan; Kaushik Banerjee; Mahmoud S Alghamri; Faisal Syed; Padma Kadiyala; Felipe J Nunez; Marianela Candolfi; Antonela Asad; Nazareno Gonzalez; Marisa E Aikins; Anna Schwendeman; James J Moon; Pedro R Lowenstein; Maria G Castro
Journal:  Front Oncol       Date:  2021-06-08       Impact factor: 5.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.